Sutro Biopharma Inc diskutieren
Sutro Biopharma Inc
WKN: A2N6SG / Symbol: STRO / Name: Sutro Biopharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
3,96 €
11,24 %
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Wedbush from $20.00 to $12.00. They now have an "outperform" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $25.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $12.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Piper Sandler from $18.00 to $12.00. They now have an "overweight" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at HC Wainwright from $16.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Wedbush from $12.00 to $8.00. They now have an "outperform" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $12.00.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Neueste Beiträge
Needham___Company_LL in Sapiens International Corporation NV diskutieren